Health ❯ Pharmaceuticals

Drug Candidates

Clinical Trials Clinical Development Phase II Trials Antisense Oligonucleotides FDA Approval Process GLP-2 Obesity Treatments

MapLight’s Schizophrenia Candidate Posts Mixed Phase II Results as Shares Plummet

A twice-daily regimen hit key efficacy measures prompting MapLight to seek FDA input on a registrational trial.

Lilly Secures Global Rights to Hanmi’s Sonefpeglutide

UCB to Buy Candid Therapeutics for Up to $2.2 Billion

Novartis to Acquire Excellergy in Up to $2 Billion Deal for Next-Gen Anti-IgE

Novo Nordisk Licenses Omeros’ MASP-3 Drug in Deal Worth Up to $2.1 Billion